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Summary
Emergency conditions in oncology may arise either as part of the malignant disease itself, or may be associated with 
its treatment. They are potentially life-threatening conditions that require urgent care, often with patient hospitalization and 
a multidisciplinary treatment approach. Consequently, it is important that all physicians are familiar not only with potential 
oncological emergencies which may occur in their clinical practice but also how to provide the most effective care in a 
timely fashion. In this review article we comprise the clinical features and treatment of several of these emergencies, name-
ly the superior vena cava syndrome (SVCS), elevated intracranial pressure, metastatic spinal cord compression (MSCC), 
hypercalcemia and febrile neutropenia.
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HITNA STANJA U ONKOLOGIJI
Sažetak
Hitna stanja u onkologiji mogu nastati kao posljedica prisustva maligne bolesti ili mogu biti povezana s liječenjem. To 
su stanja potencijalno opasna po život koja zahtijevaju hitno zbrinjavanje, često uz hospitalizaciju bolesnika, te multidisci-
plinarni terapijski pristup. Stoga je važno da svi liječnici budu upoznati s mogućim hitnim onkološkim stanjima koja se 
mogu pojaviti u njihovoj kliničkoj praksi i kako na vrijeme pružiti najučinkovitije liječenje. U ovom preglednom članku 
obuhvatili smo klinička obilježja i liječenje sindroma gornje šuplje vene, povišenog intrakranijskog tlaka, metastatske kom-
presije leđne moždine, hiperkalcemije i febrilne neutropenije.
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An oncological emergency is an acute event 
related to a patient’s tumor or its treatment, which, 
if left untreated, can lead to morbidity or death. 
Worldwide, cancer is the second cause of death af-
ter cardiovascular diseases (1). The advances in on-
cology and the subsequent growing population of 
cancer survivors necessitate familiarity with the 
diagnosis and treatment of common oncological 
emergencies. Unique complications that require an 
urgent evaluation are often left to general and 
emergency department practitioners. Timely diag-
nosis and treatment can significantly improve the 
quality of life and decrease the mortality rate of pa-
tients with malignant disease who present to the 
emergency department (2). Sometimes, an emer-
gency can be the initial presentation of cancer, 
 particularly metastatic spinal cord compression 
(MSCC) or superior vena cava syndrome (SVCS). 
A recent retrospective cross-sectional study showed 
that the most common type of neoplasm in cancer 
patients who visited the emergency department 
was a solid metastatic lesion, located in either the 
brain or the gastrointestinal tract, in stage III and 
IV, and found in patients currently undergoing 
chemo- and/or radiotherapy (2).
The most common emergencies, which are 
discussed in this paper, include SVCS, MSCC, 
raised intracranial pressure, hypercalcemia, and 
febrile neutropenia. 
SUPERIOR VENA CAVA SYNDROME  
(SVCS)
Superior vena cava syndrome (SVCS) is 
caused by the compression of the superior caval 
vein, its tumor invasion or a intraluminal throm-
bus inside of it. Subsequently, the venous drain-
age from the head, neck, thorax, and upper ex-
tremities is impaired, and the cardiac output is 
decreased. The most common malignancies asso-
ciated with this condition are lung cancer (75%), 
lymphoma (15%), and metastatic disease (3).
No correlation has been found between 
symptom duration and long term outcome for 
most cases of SVCS, regardless of the treatment 
performed (radiation, stenting, or chemotherapy) 
(4). The disease usually advances slowly, resulting 
in the development of collateral circulation in the 
azygous venous system. However, sometimes a 
rapid obstruction of the vein occurs, causing 
raised intracranial pressure and cerebral edema. 
Patients typically present to the ER with shortness 
of breath accompanied with facial and upper ex-
tremity edema with venous dilatation of the neck 
as well as the thoracic wall (5). Considering the 
slowly advancing nature of the disease, SVCS is 
rarely an acute emergency, enabling enough time 
to perform diagnostic workup. If there is no histo-
logical/cytological evidence of malignancy, a chest 
X-ray, a CT scan of the thorax, and a biopsy should 
be performed (5).
The treatment and prognosis of this condition 
depend on the underlying disease. Initial treatment 
includes a sitting position for the patient, oxygen 
therapy if necessary, and corticosteroids with gas-
tric protection. A vena cava stent can be implanted 
in order to alleviate symptoms and allow sufficient 
time to acquire a histological confirmation. If pres-
ent, thrombosis should be treated (3).
Radiotherapy has been considered for a long 
time as the quickest treatment for symptom relief, 
with or without the addition of steroids. Symp-
toms usually improve in 3-9 days. However, 
worth noting is that, in some cases, improvement 
hasn’t been reported until up to 30 days after the 
initial treatment (6). Also, percutaneous stenting 
has been proven to relieve symptoms within hours 
of the procedure, but it should only be considered 
for patients for which other treatment options are 
limited (e.g., patients with mesotheliomas) (7).
While urgent chemotherapy is an option for 
chemosensitive tumors such as lymphomas, ra-
diotherapy remains the treatment of choice for 
solitary tumors causing this condition (3). During 
radiation therapy procedure, the patient should 
lie on his back, and the radiation field should not 
only include the tumor and mediastinum, but the 
superior vena cava as well. The doses depend on 
the patients’ performance status (PS). For patients 
with a poor PS, a single dose of 10 Gy or 16 Gy in 
two doses delivers reasonable symptom control if 
the field size is smaller than 12x12cm. Patients 
with good PS and a localized disease can receive 
36 Gy in 12 fractions. Carefully selected patients 
with lung cancer can receive a radical dose (3). 
ELEVATED INTRACRANIAL PRESSURE
Brain metastases are the most common cause 
of increased intracranial pressure in cancer pa-
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tients, with melanoma and lung cancer being the 
most frequent primary lesion. Other causes of ele-
vated intracranial pressure include brain hemor-
rhage, cerebral edema, or infection (8). Most pa-
tients develop symptoms over days or weeks, with 
morning headache being the most common pre-
senting symptom. Focal neurologic deficits and 
epileptic seizures, can also frequently be a present-
ing symptom(8). After the physical exam and blood 
test, a brain CT scan should be the next step in the 
diagnostic workup. A lumbar puncture can be used 
to measure cerebral spinal fluid pressure. Howev-
er, it MUST not be performed before a CT scan ex-
cludes any neoplastic lesions, in which case a lum-
bar puncture is contraindicated. A brain MRI can 
be useful in the differentiation between neoplastic, 
infectious, and ischemic processes (3).
In some cases, such as in patients with hydro-
cephalus, an urgent neurosurgical intervention is 
sometimes necessary. In patients with vasogenic 
edema, mannitol 20-25% with dexamethasone or 
even mechanical hyperventilation can be useful. 
Fluid overload should be avoided (8). Radiothera-
py is used for the treatment of patients with brain 
metastases. If the patient has more than three brain 
metastases, a whole-brain radiation remains the 
standard of care. However, if the patient presents 
with three or less metastases, stereotactic ablative 
radiotherapy or surgery can be considered (3).
SPINAL CORD COMPRESSION
Metastatic spinal cord compression (MSCC) 
is defined as spinal cord or cauda equina com-
pression, either by direct pressure and/or induc-
tion of vertebral collapse, instability by metastatic 
spread or by direct extension of the malignant le-
sion (3). An Ontario population-based study 
found that the cumulative probability of experi-
encing at least one episode of MSCC in the five 
years preceding death from cancer was 2.5% over-
all, and ranged from 0.2% in cancer of the pancre-
as to 7.9% in myeloma (9). Spinal cord compres-
sion is the second most frequent neurological 
complication of cancer, the first one being brain 
metastases (8). This condition is commonly associ-
ated with breast, lung, and prostate cancer, as well 
as multiple myeloma (3). Signs and symptoms de-
pend on the level of compression. Seeing as the 
spinal cord ends at the level of the first lumbar 
vertebrae, compression below this level results in 
lower motor neuron symptoms, and compression 
above L1, upper motor neuron symptoms. Muscle 
weakness usually develops before sensory or au-
tonomous nervous system symptoms (3). Current 
NICE guidelines recommend informing patients 
not only about the risk of developing MSCC and 
its possible symptoms, but also advises on what to 
do if they develop them (10).
MRI should be performed when there is a 
suspected MSCC, or a CT scan if there is a contra-
indication for MRI. NICE guidelines recommend 
an MRI within one week of symptom develop-
ment. Plain radiographs are not recommended for 
the diagnosis of MSCC (10).
A multidisciplinary approach is necessary 
when dealing with this condition. Surgery should 
be performed to prevent cases of MSCC and in se-
lected patients with vertebral metastases accom-
panied by spinal instability or unmanageable 
pain. Surgery should also be considered in pa-
tients who have already developed MSCC but 
have a good prognosis and the remaining ability 
to walk, sensory or motor functions. Patients 
should start treatment with dexamethasone 16mg 
daily while awaiting radiotherapy or surgery, af-
ter which the dose should be gradually reduced 
during 5-7 days, and then stopped. Fractionated 
radiotherapy should be offered as the definitive 
treatment of choice to patients with epidural tu-
mors without neurological impairment, mechani-
cal pain, or spinal instability and to patients with 
a good prognosis who are having radiotherapy as 
their first-line treatment. Postoperative fractionat-
ed radiotherapy should be offered to all patients 
with a good surgical outcome. Patients with tetra- 
or paraplegia lasting for more than 24 hours or 
have an overall poor prognosis should not be of-
fered urgent radiotherapy (10).
A recently published meta-analysis showed 
better local control rates, but with no difference in 
survival rates and motor function outcome in pa-
tients who received long course radiotherapy (>2 
weeks) compared to short course radiotherapy (<2 
weeks). Considering better patient’s compliance 
as well as a possible lower cost of treatment, short 
course radiotherapy remains a viable treatment 
option (11).
HYPERCALCEMIA
Hypercalcemia is defined as a serum calcium 
level over 2.6 mmol/L. In patients who have bone 
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metastases, skeletal resorption is the leading cause 
of elevated serum calcium. In other patients, hy-
percalcemia can be also caused by circulating fac-
tors such as parathyroid hormone-related pep-
tide- PTH-RP and 1,25 dihydroxy vitamin D. Ma-
lignant hypercalcemias have a poor prognosis (3). 
Over 30% of patients with advanced solid tumors 
develop malignant hypercalcemia, with symp-
toms such as nausea, vomiting, obstipation, stom-
achache, tiredness, polyuria, polydipsia, and con-
fusion. If left untreated, hypercalcemia leads to 
coma and death (8).
Lab blood tests are the fastest and first step in 
diagnosing hypercalcemia. An ECG can show a 
prolonged PR interval and wide QRS complexes 
(8). The treatment of this condition depends on 
the level of calcium. Patients with serum levels 
under 3.0 mmol/L should be adequately hydrated, 
advised to keep active, and be closely monitored. 
In the case of higher calcium levels, 3 liters of the 
saline solution should be administered for 24 
hours, with careful monitoring or urine excretion, 
which should be 100-150 mL/h. Thiazide diuretics 
are not advised, furosemide application should be 
held off until dehydration correction (3). Bisphos-
phonates promote the apoptosis of osteoclasts ac-
tively engaged in the degradation of mineral on 
the bone surface and have a quick and long term 
effect. Zoledronate is currently the best choice for 
these patients, achieving serum calcium normal-
ization in 4 to 6 weeks, but caution is advised for 
possible side effects such as jaw osteonecrosis (8).
FEBRILE NEUTROPENIA
Neutropenia associated with fever can be a se-
vere and life-threatening complication of chemo-
therapy. NICE defines febrile neutropenia as a fe-
ver over 38°C or other clinical signs of infection in 
patients receiving chemotherapy whose absolute 
neutrophil count (ANC) is 0.5×10 9/L or lower (8).
Pathogens that cause febrile neutropenia in-
clude gram-negative bacteria (P. aeruginosa, E. coli, 
Kl. pneumoniae) and gram-positive bacteria (staph-
ylococcus spp., streptococcus spp., enterococcus 
spp.). No specific organism can be identified in 75-
80% of cases (8). Patients usually present with fe-
ver, low ANC, and a history of recent chemother-
apy applications. Hypotension is a dangerous 
complication that can lead to multiple organ fail-
ure (kidney, brain, liver) (3). All patients with a 
suspected diagnosis of febrile neutropenia should 
have a full blood count, kidney and liver function 
tests, CRP, blood cultures, and urine tests. Addi-
tional investigations, such as chest and abdomen 
X-ray, should be done based upon clinical presen-
tation (3).
Patients can be stratified based on the risk of 
serious complications using the MASCC Risk-In-
dex score (Multinational Association for Support-
ive Care in Cancer – MASCC). MASCC takes into 
account the presence or absence of hypotension, 
burden of illness, history of chronic obstructive 
pulmonary disease, history of fungal infection, 
volume status, tumor type (solid vs. liquid), and 
age. A patient with a total score of 21 or higher is 
considered as a lower risk one and can be treated 
as an outpatient. Broad-spectrum antibiotics 
should be administered within 60 minutes once 
NF is identified, and appropriate cultures have 
been obtained (12). Recommendations for outpa-
tient patients are ciprofloxacin 750 mg twice daily 
with amoxicillin/clavulanate 500 to 125mg every 8 
hours or moxifloxacin alternatively. Outpatient 
therapy should be continued for seven days or at 
least until the patient has been afebrile for 4-5 
days, with daily visits. High-risk patients (MAS-
CC score higher than 21) should be hospitalized 
for IV antibiotic application and monitoring. Once 
the diagnosis has been made and the cultures 
were drawn, empiric IV antibiotics should be 
started. Monotherapy (cefepime, meropenem, zo-
syn) and dual therapy (an aminoglycoside in ad-
dition to either piperacillin, cefepime, ceftazidime) 
agents are commonly used. However, if there is an 
increased risk of gram-positive bacteremia (pa-
tients with catheter-related infections, severe sep-
sis with hypotension) an additional antibiotic 
should be added, usually vancomycin. It is impor-
tant to recognize signs of septic shock as these pa-
tients should be transported into an intensive care 
unit. If, after four days, myeloid recovery does not 
appear to be imminent, a CT scan of sinuses and 
lungs can be considered, with adding antifungal 
therapy (8, 12).
CONCLUSION
Oncological emergencies may be seen in any 
emergency medical service and will become more 
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frequent as our population ages and more patients 
are treated because of malignant diseases. Physi-
cians can, therefore, expect to meet such patients 
in emergency departments as well as in outpatient 
clinics. Quick evaluation and diagnosis with the 
introduction of proper therapy can save lives and 
prevent irreversible morbidity. The management 
of oncological emergencies requires a multidisci-
plinary approach, and it is essential that all health 
care professionals have sound knowledge of these 
conditions. 
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